IO Biotech Announces Third Clinical Collaboration with Merck to Evaluate IO102-IO103 in Combination With KEYTRUDA® (pembrolizumab) as First-Line Treatment in a Phase 2 Multi-Arm Basket Trial

David Linetsky
Point-of-Care Marketing

Daniel Sontupe
Market Access

Joey Cohen
Medication Adherence

Bud Bilanich
Success Coach

Brenda Snow
Authentic Patient Voice

Paul Theisen
Patient Acquisition

Matt Turner
Patient Affordability

Amy Giles
Increasing Engagement

Pat Purcell
Meeting Engagement

Liz Kane
Impactful Strategy

Stacey Gandler
Brand Nourishment

Matthew Durham
Omnidynamic Marketing

Suma Ramadas, PhD
Medical Affairs

Frank Burrell
Scientific Storytelling